文献速递临床试验与 GCP基础与转化研究

经口内镜下肌切开术与球囊扩张治疗初治贲门失弛缓症的随机对照试验

Effect of Peroral Endoscopic Myotomy vs Pneumatic Dilation on Symptom Severity and Treatment Outcomes Among Treatment-Naive Patients With Achalasia: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

该多中心随机对照试验纳入133例初治贲门失弛缓症患者,比较经口内镜下肌切开术(POEM)与球囊扩张的疗效。2年随访时POEM组治疗成功率92%,显著高于球囊扩张组的54%(差38%,95%CI 22%-52%,P<.001),但POEM组反流性食管炎发生率更高(41% vs 7%)。

要点

  • 初治贲门失弛缓症患者POEM治疗2年成功率达92%,显著优于球囊扩张的54%。
  • POEM组反流性食管炎发生率41%,显著高于球囊扩张组的7%。
  • POEM可作为初治贲门失弛缓症的首选治疗选择之一。

核心结论

  • 在初治贲门失弛缓症患者中,POEM较球囊扩张在2年时获得显著更高的治疗成功率。
  • 这些发现支持将POEM作为贲门失弛缓症的初始治疗选择之一。

研究设计与样本

  • 随机多中心临床试验,在荷兰、德国、意大利、香港和美国的6家医院开展。
  • 纳入新诊断且Eckardt评分大于3、未接受过治疗的成人贲门失弛缓症患者。
  • 随机分为POEM组(n=67)或球囊扩张组(n=66,使用30mm和35mm球囊),按医院分层。
  • 133例随机患者中130例接受治疗(平均年龄48.6岁,73例[56%]男性),126例(95%)完成研究。

主要发现

  • 主要结局治疗成功(Eckardt评分≤3且无严重并发症或再治疗)在POEM组为58/63(92%),球囊扩张组为34/63(54%),差异38%(95%CI 22%-52%,P<.001)。
  • 14个预设次要终点中10个无显著组间差异。
  • 下食管括约肌中位整合松弛压POEM组9.9 mmHg vs 球囊扩张组12.6 mmHg,差异2.7 mmHg(95%CI -2.1至7.5,P=.07)。
  • 中位钡柱高度POEM组2.3 cm vs 球囊扩张组0 cm,差异2.3 cm(95%CI 1.0-3.6,P=.05)。
  • 反流性食管炎POEM组22/54(41%)vs 球囊扩张组2/29(7%),差异34%(95%CI 12%-49%,P=.002)。

关键数值与推荐

  • 主要结局治疗成功定义为Eckardt评分≤3且无严重并发症或再治疗,于2年随访时评估。

临床怎么用

  • 对于初治贲门失弛缓症患者,可考虑将POEM作为初始治疗选项。
  • 选择POEM时应告知患者反流性食管炎发生风险较高(41% vs 7%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Case series suggest favorable results of peroral endoscopic myotomy (POEM) for treatment of patients with achalasia. Data comparing POEM with pneumatic dilation, the standard treatment for patients with achalasia, are lacking. OBJECTIVE: To compare the effects of POEM vs pneumatic dilation as initial treatment of treatment-naive patients with achalasia. DESIGN, SETTING, AND PARTICIPANTS: This randomized multicenter clinical trial was conducted at 6 hospitals in the Netherlands, Germany, Italy, Hong Kong, and the United States. Adult patients with newly diagnosed achalasia and an Eckardt score greater than 3 who had not undergone previous treatment were included. The study was conducted between September 2012 and July 2015, the duration of follow-up was 2 years after the initial treatment, and the final date of follow-up was November 22, 2017. INTERVENTIONS: Randomization to receive POEM (n = 67) or pneumatic dilation with a 30-mm and a 35-mm balloon (n = 66), with stratification according to hospital. MAIN OUTCOMES AND MEASURES: The primary outcome was treatment success (defined as an Eckardt score ≤3 and the absence of severe complications or re-treatment) at the 2-year follow-up. A total of 14 secondary end points were examined among patients without treatment failure, including integrated relaxation pressure of the lower esophageal sphincter via high-resolution manometry, barium column height on timed barium esophagogram, and presence of reflux esophagitis. RESULTS: Of the 133 randomized patients, 130 (mean age, 48.6 years; 73 [56%] men) underwent treatment (64 in the POEM group and 66 in the pneumatic dilation group) and 126 (95%) completed the study. The primary outcome of treatment success occurred in 58 of 63 patients (92%) in the POEM group vs 34 of 63 (54%) in the pneumatic dilation group, a difference of 38% ([95% CI, 22%-52%]; P < .001). Of the 14 prespecified secondary end points, no significant difference between groups was demonstrated in 10 end points. There was no significant between-group difference in median integrated relaxation pressure (9.9 mm Hg in the POEM group vs 12.6 mm Hg in the pneumatic dilation group; difference, 2.7 mm Hg [95% CI, -2.1 to 7.5]; P = .07) or median barium column height (2.3 cm in the POEM group vs 0 cm in the pneumatic dilation group; difference, 2.3 cm [95% CI, 1.0-3.6]; P = .05). Reflux esophagitis occurred more often in the POEM group than in the pneumatic dilation group (22 of 54 [41%] vs 2 of 29 [7%]; difference, 34% [95% CI, 12%-49%]; P = .002). Two serious adverse events, including 1 perforation, occurred after pneumatic dilation, while no serious adverse events occurred after POEM. CONCLUSIONS AND RELEVANCE: Among treatment-naive patients with achalasia, treatment with POEM compared with pneumatic dilation resulted in a significantly higher treatment success rate at 2 years. These findings support consideration of POEM as an initial treatment option for patients with achalasia. TRIAL REGISTRATION: Netherlands Trial Register number: NTR3593.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ponds FA, Fockens P, Lei A, et al. Effect of Peroral Endoscopic Myotomy vs Pneumatic Dilation on Symptom Severity and Treatment Outcomes Among Treatment-Naive Patients With Achalasia: A Randomized Clinical Trial. JAMA. 2019. PMID: 31287522. doi:10.1001/jama.2019.8859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。